Literature DB >> 8892589

Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas.

R Soong1, P D Robbins, B R Dix, F Grieu, B Lim, S Knowles, K E Williams, G R Turbett, A K House, B J Iacopetta.   

Abstract

Immunohistochemical (IHC) detection of p53 protein was compared with the presence of p53 gene mutation in many colorectal (n = 100), breast (n = 92), endometrial (n = 122), and gastric (n = 116) carcinomas. Two commercially available antibodies, DO7 and CM1, were used for IHC analysis of paraffin-embedded tissue sections. Screening for gene mutations in frozen and paraffin-embedded tumor samples was carried out using polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP). The frequency of nuclear staining with DO7 or CM1 for each tumor type, respectively, was colorectal (36%, 23%); breast (15%, 19%); endometrial (21%, 33%); and gastric (23%,-). Overall correlation between the two antibodies for nuclear staining was 90% for the 314 tumors analyzed. Cytoplasmic staining was observed with DO7 in 7% of breast and 5% of gastric carcinomas and with CM1 in 17% of breast and 54% of endometrial carcinomas. p53 gene mutation was found in 39% of colorectal, 28% of breast, 13% of endometrial, and 25% of gastric cancers. The concordance between p53 nuclear overexpression and gene mutation (both positive or both negative) was 68% for colorectal, 79% for breast, 76% for endometrial, and 73% for gastric carcinomas. This study provides further evidence that IHC detection of p53 protein accumulation does not always indicate the presence of a gene mutation and vice versa. Discordant results were observed in approximately 20% to 30% of the tumors studied, highlighting the need for careful characterization of both p53 gene and protein alterations when assessing the relationship between p53 status and tumor behavior.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892589     DOI: 10.1016/s0046-8177(96)90282-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  36 in total

1.  RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.

Authors:  Mohd Feroz Mohd Omar; Kosei Ito; Min En Nga; Ross Soo; Bee Keow Peh; Tuty Muliana Ismail; Bhavin Thakkar; Richie Soong; Yoshiaki Ito; Manuel Salto-Tellez
Journal:  Pathol Oncol Res       Date:  2012-06-24       Impact factor: 3.201

2.  Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history.

Authors:  G Keller; M Rudelius; H Vogelsang; V Grimm; M G Wilhelm; J Mueller; J R Siewert; H Höfler
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

3.  Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.

Authors:  Chaar Ines; Ounissi Donia; Boughriba Rahma; Azza Ben Ammar; Amara Sameh; Taher Khalfallah; Ben Hmida Abdelmajid; Mzabi Sabeh; Bouraoui Saadia
Journal:  Tumour Biol       Date:  2014-04-25

4.  TP53 promoter methylation in primary glioblastoma: relationship with TP53 mRNA and protein expression and mutation status.

Authors:  Dorota Jesionek-Kupnicka; Malgorzata Szybka; Beata Malachowska; Wojciech Fendler; Piotr Potemski; Sylwester Piaskowski; Dariusz Jaskolski; Wielislaw Papierz; Wieslaw Skowronski; Waldemar Och; Radzislaw Kordek; Izabela Zawlik
Journal:  DNA Cell Biol       Date:  2014-02-07       Impact factor: 3.311

5.  The role of cell proliferation and crypt fission in adenoma aggressiveness: a comparison of ileoanal pouch and rectal adenomas in familial adenomatous polyposis.

Authors:  O C C Will; M Deheragoda; R K S Phillips; S K Clark; I P M Tomlinson
Journal:  Colorectal Dis       Date:  2011-04       Impact factor: 3.788

6.  Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.

Authors:  Pooja Malhotra; Mumtaz Anwar; Neha Nanda; Rakesh Kochhar; Jai Dev Wig; Kim Vaiphei; Safrun Mahmood
Journal:  Tumour Biol       Date:  2013-03-24

7.  BK virus as a cofactor in the etiology of prostate cancer in its early stages.

Authors:  Dweepanita Das; Kirk Wojno; Michael J Imperiale
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

8.  A metabolic prosurvival role for PML in breast cancer.

Authors:  Arkaitz Carracedo; Dror Weiss; Amy K Leliaert; Manoj Bhasin; Vincent C J de Boer; Gaelle Laurent; Andrew C Adams; Maria Sundvall; Su Jung Song; Keisuke Ito; Lydia S Finley; Ainara Egia; Towia Libermann; Zachary Gerhart-Hines; Pere Puigserver; Marcia C Haigis; Elefteria Maratos-Flier; Andrea L Richardson; Zachary T Schafer; Pier P Pandolfi
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

9.  Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance.

Authors:  Rui Li; Wei-Chang Chen; Xue-Qin Pang; Chen Hua; Ling Li; Xue-Guang Zhang
Journal:  Int J Mol Sci       Date:  2009-09-04       Impact factor: 6.208

10.  cDNA sequencing improves the detection of P53 missense mutations in colorectal cancer.

Authors:  Malgorzata Szybka; Magdalena Zakrzewska; Piotr Rieske; Grazyna Pasz-Walczak; Dominika Kulczycka-Wojdala; Izabela Zawlik; Robert Stawski; Dorota Jesionek-Kupnicka; Pawel P Liberski; Radzislaw Kordek
Journal:  BMC Cancer       Date:  2009-08-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.